The Spain Investors Day highlights the key role of the pharmaceutical sector for the reindustrialisation of Spain.

Juan López-Belmonte, CEO of ROVI and vice-president of Farmaindustria, highlighted at the Spain Investors Day the potential of our country as an investment destination for reindustrialisation, highlighting the pharmaceutical sector for its ability to play a decisive role in this regard. “Spain can become a hub for the production of medicines for Europe,” said Juan López-Belmonte.

The sector’s commitment is clear and forward-looking. Over the next three years, pharmaceutical companies plan to invest more than 2.7 billion euros in Spain alone to strengthen manufacturing capacities for strategic medicines, new therapies and vaccines, the digitalisation of production processes and energy efficiency.

These investments must be added to the 4.5 billion euros that the industry will allocate to research and development for the same period, as well as a further 1 billion euros planned for global activities of technological or strategic content. “At Farmaindustria we are working to make Spain a champion in the chemical sector,” said López-Belmonte.

ROVI tops the list of top-scoring pharmaceutical companies in the Reporta report

Laboratorios Farmacéuticos ROVI is positioned as the top-scoring pharmaceutical company in the latest Informe Reporta, the ranking prepared by the consultancy firm DEVA to evaluate the information provided by listed companies to their stakeholders.

In the 2022 edition, with a total of 75.2 points out of 100, ROVI is the leader in the Consumer Goods sector and 15th in the overall ranking, ahead of Inditex (20th), Grifols (30th), Pharma Mar (69th) and Almirall (79th).

This ranking evaluates 110 companies in Spain through its annual reports, classifying them on the basis of four indicators: Transparency, Commitment, Relevance and Accessibility. This year, Banco Santander (85.5 points), CIE Automotive (85.7 points) and Fluidra (84.6 points) lead the ranking.

It should be noted that, despite the fact that the average score of the companies evaluated has reached an all-time high of 48 points, almost half of the companies (49.1%) do not reach the pass mark of 50 points.

Take a look at the overall results at http://informereporta.com/.